← All trials
NCT04503733
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2020
- Primary completion
- Sep 3, 2021
- Completion date
- Jun 10, 2022
- First posted
- Aug 7, 2020
- Last posted
- Aug 7, 2020
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gmax Biopharm Australia Pty Ltd.Lead sponsor
- Central South UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
- Shantou UniversityOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- Ohio State UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.